← Back to Clinical Trials
Recruiting NCT00710177

NCT00710177 PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00710177
Status Recruiting
Phase
Sponsor Medical College of Wisconsin
Condition Persistent Pulmonary Hypertension of the Newborn
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2006-01
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 12 Months
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2006-01 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Eligibility Criteria

Inclusion Criteria: * Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age. Exclusion Criteria: * Patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

Contact & Investigator

Central Contact

G. Ganesh Konduri, MD

✉ gkonduri@mcw.edu

📞 414-266-6820

Principal Investigator

G. Ganesh Konduri, MD

PRINCIPAL INVESTIGATOR

Medical College of Wisconsin

Frequently Asked Questions

Who can join the NCT00710177 clinical trial?

This trial is open to participants of all sexes, up to 12 Months, studying Persistent Pulmonary Hypertension of the Newborn. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00710177 currently recruiting?

Yes, NCT00710177 is actively recruiting participants. Contact the research team at gkonduri@mcw.edu for enrollment information.

Where is the NCT00710177 trial being conducted?

This trial is being conducted at Milwaukee, United States.

Who is sponsoring the NCT00710177 clinical trial?

NCT00710177 is sponsored by Medical College of Wisconsin. The principal investigator is G. Ganesh Konduri, MD at Medical College of Wisconsin. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology